logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
7/23/2018 7:04:35 AM Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of SB-318 For MPS I
7/23/2018 2:33:52 AM Sangamo Therapeutics To Acquire TxCell At EUR 2.58 Per Share In Cash, Or EUR 72 Mln
7/13/2018 4:20:37 PM Sangamo Therapeutics Announces Resignation Of Michael Holmes As SVP And Chief Technology Officer
6/28/2018 4:10:42 PM Sangamo Therapeutics Appoints Karen Smith To Its Board Of Directors
6/4/2018 8:15:47 AM Sangamo : U.K. Authorizes For Enrollment Of Subjects Into Ongoing Phase 1/2 Clinical Trials Evaluating SB-318 And SB-913
5/21/2018 3:51:48 PM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) FY19 Estimate To -0.14 From 0.04
5/21/2018 3:51:31 PM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 19 Estimate To -0.04 From 0.01
5/21/2018 3:51:22 PM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q2 19 Estimate To -0.04 From 0.01
5/21/2018 3:51:06 PM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q1 19 Estimate To -0.02 From 0.03
5/21/2018 3:50:57 PM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 18 Estimate To -0.02 From 0.03
5/21/2018 3:50:50 PM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q3 18 Estimate To -0.02 From 0.03
5/16/2018 7:31:57 AM Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For BIVV003 To Treat Sickle Cell Disease
5/8/2018 7:10:48 AM Sangamo Therapeutics Q1 Loss Per Share $0.23, Same As Last Year
4/25/2018 9:39:45 PM Sangamo Therapeutics Prices Underwritten Public Offering Of 12.31 Mln Shares At $16.25/shr
4/24/2018 4:04:32 PM Sangamo Therapeutics Announces Proposed Public Offering Of Common Stock
4/4/2018 7:32:22 AM Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program
3/13/2018 6:33:30 AM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) FY18 Rev. Estimate To 112.8 M From 48.1 M